ASCO Endorses Pointers on Radiation Remedy for SCLC

Must Read


  • The American Society of Medical Oncology (ASCO) has endorsed pointers on radiation therapy (RT) for sufferers with small cell lung most cancers (SCLC), addressing thoracic radiotherapy for limited-stage SCLC, stereotactic physique radiotherapy (SBRT) for stage I-II node-negative SCLC, prophylactic cranial radiotherapy (PCI), and thoracic consolidation for extensive-stage SCLC.

Why this issues

  • ASCO’s endorsement of the rules, initially developed by the American Society for Radiation Oncology (ASTRO) in June 2020, comes with some clarifying feedback.

Key clarifications to ASTRO pointers

  • In sufferers with limited-stage SCLC present process chemotherapy with concomitant thoracic RT, sustaining the timing of chemotherapy is crucial for accelerated dose-intensive RT, together with twice-daily, hyperfractionated regimens.

  • Outlined ultracentral tumors as these with the planning goal quantity touching or overlapping the proximal bronchial tree, esophagus, or trachea.

  • PCI ought to stay the usual of care in limited-stage SCLC.

  • Thoracic RT to 3000 cGy in 10 fractions inside 6-8 weeks of completion of chemotherapy earlier than upkeep immunotherapy is conditionally beneficial in sufferers with extensive-stage SCLC who reply to chemotherapy and immunotherapy and have residual illness within the thorax.


Daly ME, Ismaila N, Decker RH, Higgins Ok, Owen D, Saxena A, Franklin GE, Donaldson D, Schneider BJ. Radiation Remedy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline. J Clin Oncol. 2021 Jan 27 [Epub ahead of print]. doi: 10.1200/JCO.20.03364. PMID: 33502911

This text initially appeared on Univadis, a part of the Medscape Skilled Community.

- Advertisement -
- Advertisement -

Latest News

Hypomethylating Agents in Children With Relapsed/Refractory AML

Hypomethylating agents are generally considered to be agents of choice for older adults with acute myeloid leukemia who...

The FDA’s Weak Drug Manufacturing Oversight Is A Potentially Deadly Problem

The latest setback for Johnson & Johnson’s COVID-19 vaccine was the U.S. Food and Drug Administration’s order on June 11, 2021, to discard 60...
- Advertisement -

More Articles Like This

- Advertisement -